April 4, 2025 U.S. equity futures are sharply lower in early trading (S&P futures -2.3%, Nasdaq futures -2.6%), following Thursday’s steep selloff that marked the S&P 500’s worst day since 2020. Risk sentiment remains under pressure globally, as markets digest escalating trade tensions and increased policy uncertainty. China announced a 34% tariff on all U.S. […]
ETFsector.com Daily Trading Outlook Read More »
April 3, 2025 Futures are sharply lower this morning, with the S&P 500 down 3.4% and Nasdaq off 3.8%, following a global risk-off move triggered by Trump’s harsher-than-expected tariff announcement. The rollout of reciprocal tariffs, which included higher-than-anticipated rates and few immediate exemptions, has stoked fears of retaliation, dampened hopes for negotiated relief, and escalated
ETFsector.com Daily Trading Outlook Read More »
This indicator suggests that the price of CYTK could increase, indicating that traders may want to consider buying the stock or call options.
The MACD Histogram for Cytokinetics (CYTK) turned positive on June 6, 2024. Read More »
Cytokinetics had its price target reduced by analysts at JMP Securities from $106.00 to $78.00 in a report sent to investors on Tuesday according to Benzinga.
JMP Securities reduces Cytokinetics (NASDAQ:CYTK) target price to $78.00. Read More »
Cytokinetics saw its price target lowered by analysts at JMP Securities from $106.00 to $78.00 in a report sent to investors on Tuesday, according to Benzinga.
JMP Securities has reduced Cytokinetics’ target price to $78.00. Read More »
On Thursday, Cytokinetics Inc (CYTK) saw its shares fall below the 200-day moving average of 53.87, dropping to a low of 47.59 per share.
CYTK’s stock price falls below an important moving average. Read More »
Cytokinetics, Incorporated revealed the pricing of an underwritten public offering of 9,803,922 shares on May 22, 2024.
Cytokinetics has announced the pricing of their public offering of common stock. Read More »
Cytokinetics, Incorporated has announced the pricing of an underwritten public offering of 9,803,922 shares of its stock.
Cytokinetics has disclosed the pricing of the public offering of its common stock. Read More »
Stay updated with the latests analysis and insights fromm etfsector.com
